[go: up one dir, main page]

HK1115890A1 - 对抗可溶性cea的医药成分 - Google Patents

对抗可溶性cea的医药成分

Info

Publication number
HK1115890A1
HK1115890A1 HK08111613.6A HK08111613A HK1115890A1 HK 1115890 A1 HK1115890 A1 HK 1115890A1 HK 08111613 A HK08111613 A HK 08111613A HK 1115890 A1 HK1115890 A1 HK 1115890A1
Authority
HK
Hong Kong
Prior art keywords
human
pharmaceutical compositions
binding domain
resistance
single chain
Prior art date
Application number
HK08111613.6A
Other languages
English (en)
Other versions
HK1115890B (zh
Inventor
Ralf Lutterbüse
Petra Mayer
Evelyne Schaller
Doris Rau
Susanne Mangold
Peter Kufer
Alexander Murr
Monika Wissinger
Tobias Raum
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of HK1115890A1 publication Critical patent/HK1115890A1/zh
Publication of HK1115890B publication Critical patent/HK1115890B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
HK08111613.6A 2005-12-21 2006-12-21 对抗可溶性cea的医药成分 HK1115890B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75196305P 2005-12-21 2005-12-21
US60/751,963 2005-12-21
EP05028064.3 2005-12-21
EP05028064 2005-12-21
US78086106P 2006-03-10 2006-03-10
US60/780,861 2006-03-10
PCT/EP2006/012425 WO2007071426A1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK13106215.1A Division HK1178548A (zh) 2005-12-21 2008-10-22 具有cea抗性的药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK13106215.1A Addition HK1178548A (zh) 2005-12-21 2008-10-22 具有cea抗性的药物组合物

Publications (2)

Publication Number Publication Date
HK1115890A1 true HK1115890A1 (zh) 2008-12-12
HK1115890B HK1115890B (zh) 2017-05-26

Family

ID=

Also Published As

Publication number Publication date
WO2007071426A1 (en) 2007-06-28
PT1976880T (pt) 2016-09-28
KR101287777B1 (ko) 2013-07-23
RU2426743C2 (ru) 2011-08-20
US20090226432A1 (en) 2009-09-10
RS55181B1 (sr) 2017-01-31
DK1976880T3 (en) 2016-09-26
RU2008129787A (ru) 2010-01-27
ME02581B (me) 2017-06-20
AU2006328886B2 (en) 2011-04-14
US20130273050A1 (en) 2013-10-17
CY1118053T1 (el) 2017-06-28
PL1976880T3 (pl) 2017-01-31
ES2595091T3 (es) 2016-12-27
HUE031151T2 (en) 2017-06-28
EP2527370A1 (en) 2012-11-28
US8394926B2 (en) 2013-03-12
NZ569204A (en) 2012-03-30
EP1976880A1 (en) 2008-10-08
EP1976880B1 (en) 2016-07-06
KR20080079330A (ko) 2008-08-29
RU2573893C2 (ru) 2016-01-27
JP2013056885A (ja) 2013-03-28
CA2633766A1 (en) 2007-06-28
BRPI0620632A2 (pt) 2011-12-20
JP2009520734A (ja) 2009-05-28
US9982063B2 (en) 2018-05-29
IL192277A0 (en) 2008-12-29
US20170137538A1 (en) 2017-05-18
US9695250B2 (en) 2017-07-04
AU2006328886C1 (en) 2011-11-17
CN101370827A (zh) 2009-02-18
JP5399712B2 (ja) 2014-01-29
CA2633766C (en) 2016-06-28
SG193141A1 (en) 2013-09-30
AU2006328886A1 (en) 2007-06-28
HRP20161216T1 (hr) 2016-11-18
IL192277A (en) 2016-08-31
LT1976880T (lt) 2016-10-10
ZA200805400B (en) 2009-09-30
CN101370827B (zh) 2015-10-14
RU2010148652A (ru) 2012-06-10

Similar Documents

Publication Publication Date Title
WO2007071422A3 (en) Pharmaceutical antibody compositions with resistance to soluble cea
WO2005103081A3 (en) Human monoclonal antibodies against cd20
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
NZ595235A (en) Compositions and methods for increasing muscle growth
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
WO2019215510A3 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2008022295A3 (en) Prlr-specific antibody and uses thereof
WO2010066803A3 (en) Human antibodies against human tissue factor
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2007073499A3 (en) Epha2 bite molecules and uses thereof
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2017083451A8 (en) Binding molecules specific for asct2 and uses thereof
WO2007118214A3 (en) Antibody compositions and methods for treatment of neoplastic disease
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20170526: (73) AMGEN RESEARCH (MUNICH) GMBH STAFFELSEESTRASSE 81477 MUNCHEN GERMANY

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201220